Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Corrigendum: Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury.

Velardi E, Tsai JJ, Radtke S, Cooper K, Argyropoulos KV, Jae-Hung S, Young LF, Lazrak A, Smith OM, Lieberman S, Kreines F, Shono Y, Wertheimer T, Jenq RR, Hanash AM, Narayan P, Lei Z, Moore MA, Kiem HP, van den Brink MRM, Dudakov JA.

Nat Med. 2018 Apr 10;24(4):525. doi: 10.1038/nm0418-525b.

PMID:
29634695
2.

Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity.

DeFilipp Z, Peled JU, Li S, Mahabamunuge J, Dagher Z, Slingerland AE, Del Rio C, Valles B, Kempner ME, Smith M, Brown J, Dey BR, El-Jawahri A, McAfee SL, Spitzer TR, Ballen KK, Sung AD, Dalton TE, Messina JA, Dettmer K, Liebisch G, Oefner P, Taur Y, Pamer EG, Holler E, Mansour MK, van den Brink MRM, Hohmann E, Jenq RR, Chen YB.

Blood Adv. 2018 Apr 10;2(7):745-753. doi: 10.1182/bloodadvances.2018017731.

3.

Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice.

Staffas A, Burgos da Silva M, Slingerland AE, Lazrak A, Bare CJ, Holman CD, Docampo MD, Shono Y, Durham B, Pickard AJ, Cross JR, Stein-Thoeringer C, Velardi E, Tsai JJ, Jahn L, Jay H, Lieberman S, Smith OM, Pamer EG, Peled JU, Cohen DE, Jenq RR, van den Brink MRM.

Cell Host Microbe. 2018 Apr 11;23(4):447-457.e4. doi: 10.1016/j.chom.2018.03.002. Epub 2018 Mar 22.

PMID:
29576480
4.

The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future.

Andermann TM, Peled JU, Ho C, Reddy P, Riches M, Storb R, Teshima T, van den Brink MRM, Alousi A, Balderman S, Chiusolo P, Clark WB, Holler E, Howard A, Kean LS, Koh AY, McCarthy PL, McCarty JM, Mohty M, Nakamura R, Rezvani K, Segal BH, Shaw BE, Shpall EJ, Sung AD, Weber D, Whangbo J, Wingard JR, Wood WA, Perales MA, Jenq RR, Bhatt AS; Blood and Marrow Transplant Clinical Trials Network.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1322-1340. doi: 10.1016/j.bbmt.2018.02.009. Epub 2018 Feb 19. No abstract available.

PMID:
29471034
5.

Production of BMP4 by endothelial cells is crucial for endogenous thymic regeneration.

Wertheimer T, Velardi E, Tsai J, Cooper K, Xiao S, Kloss CC, Ottmüller KJ, Mokhtari Z, Brede C, deRoos P, Kinsella S, Palikuqi B, Ginsberg M, Young LF, Kreines F, Lieberman SR, Lazrak A, Guo P, Malard F, Smith OM, Shono Y, Jenq RR, Hanash AM, Nolan DJ, Butler JM, Beilhack A, Manley NR, Rafii S, Dudakov JA, van den Brink MRM.

Sci Immunol. 2018 Jan 12;3(19). pii: eaal2736. doi: 10.1126/sciimmunol.aal2736.

6.

Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury.

Velardi E, Tsai JJ, Radtke S, Cooper K, Argyropoulos KV, Jae-Hung S, Young LF, Lazrak A, Smith OM, Lieberman S, Kreines F, Shono Y, Wertheimer T, Jenq RR, Hanash AM, Narayan P, Lei Z, Moore MA, Kiem HP, van den Brink MRM, Dudakov JA.

Nat Med. 2018 Feb;24(2):239-246. doi: 10.1038/nm.4470. Epub 2018 Jan 8. Erratum in: Nat Med. 2018 Apr 10;24(4):525.

7.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA.

Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2.

8.

Loss of thymic innate lymphoid cells leads to impaired thymopoiesis in experimental graft-versus-host disease.

Dudakov JA, Mertelsmann AM, O'Connor MH, Jenq RR, Velardi E, Young LF, Smith OM, Boyd RL, van den Brink MRM, Hanash AM.

Blood. 2017 Aug 17;130(7):933-942. doi: 10.1182/blood-2017-01-762658. Epub 2017 Jun 12.

9.

Protective Factors in the Intestinal Microbiome Against Clostridium difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.

Lee YJ, Arguello ES, Jenq RR, Littmann E, Kim GJ, Miller LC, Ling L, Figueroa C, Robilotti E, Perales MA, Barker JN, Giralt S, van den Brink MRM, Pamer EG, Taur Y.

J Infect Dis. 2017 Apr 1;215(7):1117-1123. doi: 10.1093/infdis/jix011.

10.

Clinical Evidence for the Microbiome in Inflammatory Diseases.

Slingerland AE, Schwabkey Z, Wiesnoski DH, Jenq RR.

Front Immunol. 2017 Apr 12;8:400. doi: 10.3389/fimmu.2017.00400. eCollection 2017. Review.

11.

RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury.

Fischer JC, Bscheider M, Eisenkolb G, Lin CC, Wintges A, Otten V, Lindemans CA, Heidegger S, Rudelius M, Monette S, Porosnicu Rodriguez KA, Calafiore M, Liebermann S, Liu C, Lienenklaus S, Weiss S, Kalinke U, Ruland J, Peschel C, Shono Y, Docampo M, Velardi E, Jenq RR, Hanash AM, Dudakov JA, Haas T, van den Brink MRM, Poeck H.

Sci Transl Med. 2017 Apr 19;9(386). pii: eaag2513. doi: 10.1126/scitranslmed.aag2513.

12.

Can Consideration of the Microbiome Improve Antimicrobial Utilization and Treatment Outcomes in the Oncology Patient?

Galloway-Peña JR, Jenq RR, Shelburne SA.

Clin Cancer Res. 2017 Jul 1;23(13):3263-3268. doi: 10.1158/1078-0432.CCR-16-3173. Epub 2017 Mar 15. Review.

13.

Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation.

Peled JU, Devlin SM, Staffas A, Lumish M, Khanin R, Littmann ER, Ling L, Kosuri S, Maloy M, Slingerland JB, Ahr KF, Porosnicu Rodriguez KA, Shono Y, Slingerland AE, Docampo MD, Sung AD, Weber D, Alousi AM, Gyurkocza B, Ponce DM, Barker JN, Perales MA, Giralt SA, Taur Y, Pamer EG, Jenq RR, van den Brink MRM.

J Clin Oncol. 2017 May 20;35(15):1650-1659. doi: 10.1200/JCO.2016.70.3348. Epub 2017 Mar 15.

14.

Lactobacillus rhamnosus GG probiotic enteric regimen does not appreciably alter the gut microbiome or provide protection against GVHD after allogeneic hematopoietic stem cell transplantation.

Gorshein E, Wei C, Ambrosy S, Budney S, Vivas J, Shenkerman A, Manago J, McGrath MK, Tyno A, Lin Y, Patel V, Gharibo M, Schaar D, Jenq RR, Khiabanian H, Strair R.

Clin Transplant. 2017 May;31(5). doi: 10.1111/ctr.12947. Epub 2017 Mar 31.

PMID:
28256022
15.

Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation.

Weber D, Jenq RR, Peled JU, Taur Y, Hiergeist A, Koestler J, Dettmer K, Weber M, Wolff D, Hahn J, Pamer EG, Herr W, Gessner A, Oefner PJ, van den Brink MRM, Holler E.

Biol Blood Marrow Transplant. 2017 May;23(5):845-852. doi: 10.1016/j.bbmt.2017.02.006. Epub 2017 Feb 14.

16.

MiRKAT-S: a community-level test of association between the microbiota and survival times.

Plantinga A, Zhan X, Zhao N, Chen J, Jenq RR, Wu MC.

Microbiome. 2017 Feb 8;5(1):17. doi: 10.1186/s40168-017-0239-9.

17.

Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.

Ghosh A, Smith M, James SE, Davila ML, Velardi E, Argyropoulos KV, Gunset G, Perna F, Kreines FM, Levy ER, Lieberman S, Jay HV, Tuckett AZ, Zakrzewski JL, Tan L, Young LF, Takvorian K, Dudakov JA, Jenq RR, Hanash AM, Motta AC, Murphy GF, Liu C, Schietinger A, Sadelain M, van den Brink MR.

Nat Med. 2017 Feb;23(2):242-249. doi: 10.1038/nm.4258. Epub 2017 Jan 9.

18.

Role of the intestinal mucosa in acute gastrointestinal GVHD.

Peled JU, Hanash AM, Jenq RR.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):119-127. Review.

19.

Role of the intestinal mucosa in acute gastrointestinal GVHD.

Peled JU, Hanash AM, Jenq RR.

Blood. 2016 Nov 17;128(20):2395-2402. Review.

20.

Not just leukemia: CMV may protect against lymphoma recurrence after allogeneic transplant.

Peled JU, Jenq RR.

Leuk Lymphoma. 2017 Apr;58(4):759-761. doi: 10.1080/10428194.2016.1239265. Epub 2016 Oct 12. No abstract available.

21.

Role of gut flora after bone marrow transplantation.

Peled JU, Jenq RR, Holler E, van den Brink MR.

Nat Microbiol. 2016 Mar 29;1:16036. doi: 10.1038/nmicrobiol.2016.36. No abstract available.

22.

Antibiotic prophylaxis in allogeneic stem cell transplantation-what is the correct choice?

Jenq RR, van den Brink MR.

Bone Marrow Transplant. 2016 Aug;51(8):1071-2. doi: 10.1038/bmt.2016.144. Epub 2016 May 23. No abstract available.

PMID:
27214076
23.

Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice.

Shono Y, Docampo MD, Peled JU, Perobelli SM, Velardi E, Tsai JJ, Slingerland AE, Smith OM, Young LF, Gupta J, Lieberman SR, Jay HV, Ahr KF, Porosnicu Rodriguez KA, Xu K, Calarfiore M, Poeck H, Caballero S, Devlin SM, Rapaport F, Dudakov JA, Hanash AM, Gyurkocza B, Murphy GF, Gomes C, Liu C, Moss EL, Falconer SB, Bhatt AS, Taur Y, Pamer EG, van den Brink MRM, Jenq RR.

Sci Transl Med. 2016 May 18;8(339):339ra71. doi: 10.1126/scitranslmed.aaf2311.

24.

Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration.

Lindemans CA, Calafiore M, Mertelsmann AM, O'Connor MH, Dudakov JA, Jenq RR, Velardi E, Young LF, Smith OM, Lawrence G, Ivanov JA, Fu YY, Takashima S, Hua G, Martin ML, O'Rourke KP, Lo YH, Mokry M, Romera-Hernandez M, Cupedo T, Dow L, Nieuwenhuis EE, Shroyer NF, Liu C, Kolesnick R, van den Brink MRM, Hanash AM.

Nature. 2015 Dec 24;528(7583):560-564. doi: 10.1038/nature16460. Epub 2015 Dec 9.

25.

Role of intestinal microbiota in transplantation outcomes.

Taur Y, Jenq RR, Ubeda C, van den Brink M, Pamer EG.

Best Pract Res Clin Haematol. 2015 Jun-Sep;28(2-3):155-61. doi: 10.1016/j.beha.2015.10.013. Epub 2015 Oct 22. Review.

26.

How's your microbiota? Let's check your urine.

Jenq RR.

Blood. 2015 Oct 1;126(14):1641-2. doi: 10.1182/blood-2015-08-661504.

27.

Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease.

Jenq RR, Taur Y, Devlin SM, Ponce DM, Goldberg JD, Ahr KF, Littmann ER, Ling L, Gobourne AC, Miller LC, Docampo MD, Peled JU, Arpaia N, Cross JR, Peets TK, Lumish MA, Shono Y, Dudakov JA, Poeck H, Hanash AM, Barker JN, Perales MA, Giralt SA, Pamer EG, van den Brink MR.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1373-83. doi: 10.1016/j.bbmt.2015.04.016. Epub 2015 May 11.

28.

Gut microbiota and tacrolimus dosing in kidney transplantation.

Lee JR, Muthukumar T, Dadhania D, Taur Y, Jenq RR, Toussaint NC, Ling L, Pamer E, Suthanthiran M.

PLoS One. 2015 Mar 27;10(3):e0122399. doi: 10.1371/journal.pone.0122399. eCollection 2015.

29.

Intestinal microbiota-related effects on graft-versus-host disease.

Shono Y, Docampo MD, Peled JU, Perobelli SM, Jenq RR.

Int J Hematol. 2015 May;101(5):428-37. doi: 10.1007/s12185-015-1781-5. Epub 2015 Mar 27. Review.

30.

Emerging Influence of the Intestinal Microbiota during Allogeneic Hematopoietic Cell Transplantation: Control the Gut and the Body Will Follow.

Docampo MD, Auletta JJ, Jenq RR.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1360-6. doi: 10.1016/j.bbmt.2015.02.016. Epub 2015 Feb 21. Review.

31.

Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile.

Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, Littmann E, van den Brink MR, Jenq RR, Taur Y, Sander C, Cross JR, Toussaint NC, Xavier JB, Pamer EG.

Nature. 2015 Jan 8;517(7533):205-8. doi: 10.1038/nature13828. Epub 2014 Oct 22.

32.

The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation.

Taur Y, Jenq RR, Perales MA, Littmann ER, Morjaria S, Ling L, No D, Gobourne A, Viale A, Dahi PB, Ponce DM, Barker JN, Giralt S, van den Brink M, Pamer EG.

Blood. 2014 Aug 14;124(7):1174-82. doi: 10.1182/blood-2014-02-554725. Epub 2014 Jun 17.

33.

Early Clostridium difficile infection during allogeneic hematopoietic stem cell transplantation.

Kinnebrew MA, Lee YJ, Jenq RR, Lipuma L, Littmann ER, Gobourne A, No D, van den Brink M, Pamer EG, Taur Y.

PLoS One. 2014 Mar 24;9(3):e90158. doi: 10.1371/journal.pone.0090158. eCollection 2014.

34.

Enhanced responses to tumor immunization following total body irradiation are time-dependent.

Diab A, Jenq RR, Rizzuto GA, Cohen AD, Huggins DW, Merghoub T, Engelhorn ME, Guevara-Patiño JA, Suh D, Hubbard-Lucey VM, Kochman AA, Chen S, Zhong H, Wolchok JD, van den Brink MR, Houghton AN, Perales MA.

PLoS One. 2013 Dec 12;8(12):e82496. doi: 10.1371/journal.pone.0082496. eCollection 2013.

35.

PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD.

Ghosh A, Holland AM, Dogan Y, Yim NL, Rao UK, Young LF, West ML, Singer NV, Lee H, Na IK, Tsai JJ, Jenq RR, Penack O, Hanash AM, Lezcano C, Murphy GF, Liu C, Sadelain M, Sauer MG, Sant'angelo D, van den Brink MR.

Cancer Res. 2013 Aug 1;73(15):4687-96. doi: 10.1158/0008-5472.CAN-12-4699. Epub 2013 Jun 3.

36.

Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity.

Ghosh A, Dogan Y, Moroz M, Holland AM, Yim NL, Rao UK, Young LF, Tannenbaum D, Masih D, Velardi E, Tsai JJ, Jenq RR, Penack O, Hanash AM, Smith OM, Piersanti K, Lezcano C, Murphy GF, Liu C, Palomba ML, Sauer MG, Sadelain M, Ponomarev V, van den Brink MR.

J Clin Invest. 2013 Jun;123(6):2654-62. doi: 10.1172/JCI66301. Epub 2013 May 15.

37.

Intestinal microbiota containing Barnesiella species cures vancomycin-resistant Enterococcus faecium colonization.

Ubeda C, Bucci V, Caballero S, Djukovic A, Toussaint NC, Equinda M, Lipuma L, Ling L, Gobourne A, No D, Taur Y, Jenq RR, van den Brink MR, Xavier JB, Pamer EG.

Infect Immun. 2013 Mar;81(3):965-73. doi: 10.1128/IAI.01197-12. Epub 2013 Jan 14.

38.

Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease.

Hanash AM, Dudakov JA, Hua G, O'Connor MH, Young LF, Singer NV, West ML, Jenq RR, Holland AM, Kappel LW, Ghosh A, Tsai JJ, Rao UK, Yim NL, Smith OM, Velardi E, Hawryluk EB, Murphy GF, Liu C, Fouser LA, Kolesnick R, Blazar BR, van den Brink MR.

Immunity. 2012 Aug 24;37(2):339-50. doi: 10.1016/j.immuni.2012.05.028.

39.

Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation.

Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, Lee YJ, Dubin KA, Socci ND, Viale A, Perales MA, Jenq RR, van den Brink MR, Pamer EG.

Clin Infect Dis. 2012 Oct;55(7):905-14. doi: 10.1093/cid/cis580. Epub 2012 Jun 20.

40.

Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation.

Jenq RR, Ubeda C, Taur Y, Menezes CC, Khanin R, Dudakov JA, Liu C, West ML, Singer NV, Equinda MJ, Gobourne A, Lipuma L, Young LF, Smith OM, Ghosh A, Hanash AM, Goldberg JD, Aoyama K, Blazar BR, Pamer EG, van den Brink MR.

J Exp Med. 2012 May 7;209(5):903-11. doi: 10.1084/jem.20112408. Epub 2012 Apr 30.

41.

Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer.

Jenq RR, Curran MA, Goldberg GL, Liu C, Allison JP, van den Brink MR.

PLoS One. 2012;7(4):e35222. doi: 10.1371/journal.pone.0035222. Epub 2012 Apr 6.

42.

Interleukin-22 drives endogenous thymic regeneration in mice.

Dudakov JA, Hanash AM, Jenq RR, Young LF, Ghosh A, Singer NV, West ML, Smith OM, Holland AM, Tsai JJ, Boyd RL, van den Brink MR.

Science. 2012 Apr 6;336(6077):91-5. doi: 10.1126/science.1218004. Epub 2012 Mar 1.

43.

Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.

Lu SX, Kappel LW, Charbonneau-Allard AM, Atallah R, Holland AM, Turbide C, Hubbard VM, Rotolo JA, Smith M, Suh D, King C, Rao UK, Yim N, Bautista JL, Jenq RR, Penack O, Na IK, Liu C, Murphy G, Alpdogan O, Blumberg RS, Macian F, Holmes KV, Beauchemin N, van den Brink MR.

PLoS One. 2011;6(7):e21611. doi: 10.1371/journal.pone.0021611. Epub 2011 Jul 6.

44.

Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation.

Ponce DM, Zheng J, Gonzales AM, Lubin M, Heller G, Castro-Malaspina H, Giralt S, Hsu K, Jakubowski AA, Jenq RR, Koehne G, Papadopoulos EB, Perales MA, van den Brink MR, Young JW, Boulad F, Kernan NA, Kobos R, Prockop S, Scaradavou A, Small T, O'Reilly RJ, Barker JN.

Biol Blood Marrow Transplant. 2011 Sep;17(9):1316-26. doi: 10.1016/j.bbmt.2011.01.006. Epub 2011 Jan 11.

45.

Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans.

Ubeda C, Taur Y, Jenq RR, Equinda MJ, Son T, Samstein M, Viale A, Socci ND, van den Brink MR, Kamboj M, Pamer EG.

J Clin Invest. 2010 Dec;120(12):4332-41. doi: 10.1172/JCI43918. Epub 2010 Nov 22.

46.

Absence of P-selectin in recipients of allogeneic bone marrow transplantation ameliorates experimental graft-versus-host disease.

Lu SX, Holland AM, Na IK, Terwey TH, Alpdogan O, Bautista JL, Smith OM, Suh D, King C, Kochman A, Hubbard VM, Rao UK, Yim N, Liu C, Laga AC, Murphy G, Jenq RR, Zakrzewski JL, Penack O, Dykstra L, Bampoe K, Perez L, Furie B, Furie B, van den Brink MR.

J Immunol. 2010 Aug 1;185(3):1912-9. doi: 10.4049/jimmunol.0903148. Epub 2010 Jul 9.

47.

Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth.

Penack O, Henke E, Suh D, King CG, Smith OM, Na IK, Holland AM, Ghosh A, Lu SX, Jenq RR, Liu C, Murphy GF, Lu TT, May C, Scheinberg DA, Gao DC, Mittal V, Heller G, Benezra R, van den Brink MR.

J Natl Cancer Inst. 2010 Jun 16;102(12):894-908. doi: 10.1093/jnci/djq172. Epub 2010 May 12.

48.

Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer.

Jenq RR, van den Brink MR.

Nat Rev Cancer. 2010 Mar;10(3):213-21. doi: 10.1038/nrc2804. Epub 2010 Feb 19. Review. Erratum in: Nat Rev Cancer. 2010 Mar;10(3). doi: 10.1038/nrc2825.

PMID:
20168320
49.

The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease.

Na IK, Lu SX, Yim NL, Goldberg GL, Tsai J, Rao U, Smith OM, King CG, Suh D, Hirschhorn-Cymerman D, Palomba L, Penack O, Holland AM, Jenq RR, Ghosh A, Tran H, Merghoub T, Liu C, Sempowski GD, Ventevogel M, Beauchemin N, van den Brink MR.

J Clin Invest. 2010 Jan;120(1):343-56. doi: 10.1172/JCI39395. Epub 2009 Dec 1.

50.

Relapse after allogeneic hematopoietic cell therapy.

van den Brink MR, Porter DL, Giralt S, Lu SX, Jenq RR, Hanash A, Bishop MR.

Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S138-45. doi: 10.1016/j.bbmt.2009.10.023. Epub 2009 Oct 24. Review.

Supplemental Content

Support Center